23 research outputs found
Platinum resistance in breast and ovarian cancer cell lines
Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15% and 6%, respectively. Despite tremendous efforts to conquer malignant diseases, the war on cancer declared by Richard Nixon four decades ago seems to be lost. Approximately 21,800 women in the US will be diagnosed with ovarian cancer in 2011. Therefore, its incidence is relatively low compared to breast cancer with 207.090 prognosed cases in 2011. However, overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinum-based chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer. However, in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the world are focussing on this issue. This review covers new findings in this field during the past decade
The Impact of Social Advertising Campaigns in Shaping Egyptian Youth’s Behavioral Intentions
Obesidade e sua relação com fatores de risco para doenças cardiovasculares em uma população nipo-brasileira
The Heterogeneous Biomechanics and Mechanobiology of the Mitral Valve: Implications for Tissue Engineering
Total synchronous fluorescence spectroscopic data modeled with first- and second-order algorithms for the determination of doxorubicin in human plasma
Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option
Campylobacter jejuni cell lysates differently target mitochondria and lysosomes on HeLa cells
Campylobacter jejuni is the most common
cause of bacterial gastroenteritis in humans. The synthesis
of cytolethal distending toxin appears essential in the
infection process. In this work we evaluated the sequence
of lethal events in HeLa cells exposed to cell lysates of two
distinct strains,C. jejuniATCC 33291 andC. jejuniISS3.
C. jejunicell lysates (CCLys) were added to HeLa cell
monolayers which were analysed to detect DNA content,
death features, bcl-2 and p53 status, mitochondria/lyso-somes network and finally, CD54 and CD59 alterations,
compared to cell lysates ofC. jejuni11168HcdtA mutant.
We found mitochondria and lysosomes differently targeted
by these bacterial lysates. Death, consistent with apoptosis
for C. jejuniATCC 33291 lysate, occurred in a slow way
([48 h); concomitantly HeLa cells increase their endolys-osomal compartment, as a consequence of toxin internali-zation besides a simultaneous and partial lysosomal
destabilization.C. jejuniCCLys induces death in HeLa
cells mainly via a caspase-dependent mechanism although
a p53 lysosomal pathway (also caspase-independent) seems
to appear in addition. In C. jejuniISS3-treated cells, the
p53-mediated oxidative degradation of mitochondrial
components seems to be lost, inducing the deepest
lysosomal alterations. Furthermore, CD59 considerably
decreases, suggesting both a degradation or internalisation
pathway. CCLys-treated HeLa cells increase CD54
expression on their surface, because of the action of lysate
as its double feature of toxin and bacterial peptide. In
conclusion, we revealed thatC. jejuniCCLys-treated HeLa
cells displayed different features, depending on the par-ticular strain